4 replies to this topic

[Hedgehog]

In summary, in an HTS campaign against human recombinant
SIRT1 using a library comprising 147,000 compounds,
we have successfully identified 2 classes of compounds, activators
and inhibitors. We confirmed a set of quinoxalins with
strong activating potential on recombinant SIRT1. Compounds,
such as the SIRT1 activators 1 to 3 and the tetrahydrocarbazolebased
SIRT1 inhibitor compound 4 presented here, have the
ability to modulate the activity of SIR proteins such as SIRT1.

Attached Files

•  959.pdf   457.1KB   187 downloads

[TianZi]

In summary, in an HTS campaign against human recombinant
SIRT1 using a library comprising 147,000 compounds,
we have successfully identified 2 classes of compounds, activators
and inhibitors. We confirmed a set of quinoxalins with
strong activating potential on recombinant SIRT1. Compounds,
such as the SIRT1 activators 1 to 3 and the tetrahydrocarbazolebased
SIRT1 inhibitor compound 4 presented here, have the
ability to modulate the activity of SIR proteins such as SIRT1.

I'm an attorney, not a biologist, so reading the attached study is about as useful to me as reading a technical treatise on fee tails and the rule against perpetuities would be for a non-attorney.

With that said, this snippet from the study caught my eye:

"Resveratrol is a weak activator of SIRT1 function, thereby
providing a precedented standard for comparative studies with
these more potent activators. These compounds are at least
10-fold more potent in the in vitro suppression of TNF-α release
compared to resveratrol."

Edited by TianZi, 23 April 2008 - 04:45 AM.

[mikeinnaples]

Agreed, HH would you mind a breif explanation in layman's terms?

[Hedgehog]

In summary, in an HTS campaign against human recombinant
SIRT1 using a library comprising 147,000 compounds,
we have successfully identified 2 classes of compounds, activators
and inhibitors. We confirmed a set of quinoxalins with
strong activating potential on recombinant SIRT1. Compounds,
such as the SIRT1 activators 1 to 3 and the tetrahydrocarbazolebased
SIRT1 inhibitor compound 4 presented here, have the
ability to modulate the activity of SIR proteins such as SIRT1.

I'm an attorney, not a biologist, so reading the attached study is about as useful to me as reading a technical treatise on fee tails and the rule against perpetuities would be for a non-attorney.

With that said, this snippet from the study caught my eye:

"Resveratrol is a weak activator of SIRT1 function, thereby
providing a precedented standard for comparative studies with
these more potent activators. These compounds are at least
10-fold more potent in the in vitro suppression of TNF-α release
compared to resveratrol."

Yep that is pretty much what I got out of the paper. There are other compounds other than resveratrol that activate SIRT1 gene. These molecules look much different than resveratrol but seem to do a better job at activation. Hopefully a few of these compounds will be found to be naturally occuring.

Attached Files

•  SIRT_ACTIVATORS.JPG   39.86KB   47 downloads

[ilanso]

http://www.nih.gov/n...08/niams-12.htm

Molecular Pathway in Muscle Helps Explain Effectiveness of Diabetes Interventions

Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), demonstrate for the first time in a mouse model that skeletal muscle cells cultured in a low-calorie environment refrain from differentiating, an energy-demanding process by which cells mature and specialize. They also describe for the first time the molecular pathway (the protein-signaling system by which cells read and react to their environment), involving the protein SIRT1 that becomes activated in mouse skeletal muscle cells when they receive fewer calories. The study appears in the May 13 issue of "Developmental Cell".

The discovery of this molecular pathway in muscle is also of interest to diabetes researchers because calorie-restriction diets, as well as the drug metformin, are both treatments for type 2 diabetes and a related condition, metabolic syndrome. The treatments help the body better regulate the body’s uptake of sugar, a nutrient that people with these conditions have trouble regulating. But the exact mechanism of action of these treatments is unclear.

Vittorio Sartorelli, M.D., chief of the NIAMS’ Laboratory of Muscle Stem Cells and Gene Regulation and leader of the research team said, “We think this finding has given us a better molecular understanding of how lifestyle and drug interventions function in the treatment of type 2 diabetes and metabolic syndrome.” Skeletal muscle plays a critical role in type 2 diabetes and in a related condition, metabolic syndrome. It is responsible for more than 40 percent of the body’s uptake of sugar, a nutrient the body has trouble regulating in both conditions.

In their project, Sartorelli and his colleagues set out to investigate the relationship between skeletal muscle cells, calorie restriction, metformin and SIRT1 in mice. They cultured skeletal muscle cells from normal mice in a low-glucose environment to restrict calories and treated others with metformin. As expected, in each intervention the cells failed to mature and form myocytes, cells that are the building blocks of muscle fibers. What was new in their findings, however, was that metformin and calorie restriction both promoted the activation of two proteins, AMPK and Nampt, which in turn made SIRT1 more active and capable of suppressing cell differentiation.

When the scientists tried metformin and calorie restriction in the cells of mice engineered to have inactive SIRT1, the muscle cells ignored the suppressive effects of the interventions and remained able to produce mature myocytes. In addition, the usual changes in gene activity in response to calorie restriction in mice with inactive SIRT1 did not occur, another indication that SIRT1 is necessary to mediate the effects of calorie restriction.

Sartorelli said the team’s research shows that SIRT1 is a molecule that allows skeletal muscle to read a low amount of nutrients in the environment and suppress genes that promote cell differentiation, thereby conserving energy. He added that it also demonstrates that two interventions that can control diabetes – reduced caloric intake and metformin – both target SIRT1.